# Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

> **NCT01027377** · PHASE1 · COMPLETED · sponsor: **Bioverativ Therapeutics Inc.** · enrollment: 16 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** rFVIIIFc
- **DRUG:** rFVIIIFc

## Key facts

- **NCT ID:** NCT01027377
- **Lead sponsor:** Bioverativ Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-07
- **Final completion:** 2011-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01027377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01027377, "Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01027377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*